Mark Kroese - Director

Mark joined the Foundation in 2012 as Consultant in Public Health Medicine/Programme Director and was appointed Director in October 2017. He leads the corporate development and strategic management of the Foundation and is responsible for the delivery of its work programme.

Mark graduated in medicine from the University of Edinburgh in 1992 and trained in general practice. Following a post as District Medical Officer in the Caribbean, he returned to the UK to train in public health medicine. Appointed NHS Consultant in Public Health Medicine in 2005, Mark has considerable experience in the NHS. His special interests include healthcare public health, evaluation of genetic tests and the commissioning of clinical genetics services.

He has been a standing member of the Diagnostics Advisory Committee (DAC) of the National Institute for Health and Care Excellence (NICE) (2010-2022) and the Chair of the DAC (2017-2022). Mark has also held the following appointments; public health advisor to the NHS UK Genetic Testing Network (UKGTN) (2006-2018), member of the Council of the Royal College of Physicians of Edinburgh and the Board of the Faculty of Public Health (2017 -2021). He is an accredited clinical supervisor for the HEE East of England Public Health Training Programme.

Reports

Blogs

Journal papers

Optimising Exome Prenatal Sequencing Services (EXPRESS): a study protocol to evaluate rapid prenatal exome sequencing in the NHS Genomic Medicine Service
Melissa Hill; Sian Ellard; Jane Fisher; Naomi Fulop; Marian Knight; Mark Kroese; Jean Ledger; Kerry Leeson-Beevers; Alec McEwan; Dominic McMullan; Laura Blackburn et al. [version 2; peer review: 2 approved]. NIHR Open Res 2022, 2:10
Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention
Moorthie S, Babb de Villiers C, Burton H, Kroese M, Antoniou A.C., Bhattacharjee P, Garcia-Closas M, Hall P, Schmidt M.K.. Preventive Medicine, Vol 159. 6 May 2022.
How can we address the uncertainties regarding the potential clinical utility of polygenic score-based tests?
Moorthie S, Hall A, Babb de Villiers C, Janus J, Brigden T, Blackburn L, Kroese M. Future Medicine. 15 March 2022.
Understanding polygenic models, their development and the potential application of polygenic scores in healthcare
Babb de Villiers C, Kroese M, Moorthie S. Journal of Medical Genetics Online First. 6 May 2020.
Risk stratification, genomic data and the law.
Hall A, Finnegan T, Chowdhury S, Dent T, Kroese M, Burton H.
J Community Genet. 2018; https://doi.org/10.1007/s12687-018-0358-4. [Epub ahead of print]
Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study
Warren-Gash C, Kroese M, Burton H, Pharoah P.
Hered Cancer Clin Pract. 2016 Jun; 1;14:12.
Realising the promise of non-invasive prenatal testing
Chitty LS, Kroese M.
BMJ. 2015 Apr 10;350:1792.
Cost Effectiveness of Using Array-CGH for Diagnosing Learning Disability
Sagoo GS, Mohammed S, Barton G, Kroese M et al.
Applied Health Economics and Health Policy. 2015; 13,4, 421-432.
Personalized medicine: what's in a name?
Burton H, Hall A, Kroese M, Pokorska-Bocci A, Sagoo G, Stewart A.
Personalised Medicine. 2014; 11(2):197-210.
Points to consider for prioritizing clinical genetic testing services: a European consensus process oriented accountability for reasonableness
Borry P, Cornel M, Kroese M, Severin F.
European Journal of Human Genetics. 2014 Sept 24.
Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol
Boustred C, Chitty L, Daley R, Fisher J, Hill M, Howarth A, Kroese M, Lench N, Lewis C, Lo K, Mason S, Mckay F, Morris S, Plagnol V, Spencer K, Wright D.
BMC Pregnancy Childbirth. 2014 Jul 16; 14:229.
Personalised medicine in the UK: challenges of implementation and impact on healthcare system
Burton H, Hall A, Kroese M, Pokorska-Bocci A, Sagoo G.
Genome Medicine. 2014 Apr 25; 6(4):28.
A framework for the prioritization of investment in the provision of genetic tests
Alberg C, Burton H, Kroese M, Lakshman R, Whittaker J.
Public Health Genomics. 2010; 13 (7-8) 538-43.
Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how?
Kroese M, Wright C.
Human Genetics. 2009; doi:10.1007/s00439-009-0767-x
How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network.
Kroese M, Zimmern R, Farndon P, Stewart F, Whittaker J.
Eur J Hum Genet. 2007;15:917-21.
Defining purpose: a key step in genetic test evaluation
Burke W, Kroese M, Zimmern R.
Genetics in Medicine. 2007; 9(10):675-681
HER2 status in breast cancer - an example of pharmacogenetic testing
Kroese M, Pinder S, Zimmern R.
Journal of the Royal Society of Medicine. 2007 Jul; 100(7):326-9
The evaluation of genetic tests
Kroese M, Zimmern R.
Journal of Public Health. 2007 May 24; [Epub ahead of print]
How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom
Emery J, Higgins J, Kroese M, Patch C, Sanderson S, Zimmern R.
Genetics in Medicine. 2005; 7(7):495-500
Genetic tests and their evaluation: Can we answer the key questions?
Kroese M, Zimmern R.
Genetics in Medicine. 2004; 6(6):475-80
Gene genies
Burton H, Kroese M.
Health Service Journal. 2003; 113(5868):29

Dr Mark Kroese

Genomics and policy newsletter